vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and WOLVERINE WORLD WIDE INC (WWW). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $517.5M, roughly 1.2× WOLVERINE WORLD WIDE INC). EXELIXIS, INC. runs the higher net margin — 40.8% vs 6.1%, a 34.7% gap on every dollar of revenue. On growth, WOLVERINE WORLD WIDE INC posted the faster year-over-year revenue change (25.5% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $145.6M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 14.5%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Wolverine World Wide is a global designer, manufacturer and marketer of branded footwear, apparel and accessories. It owns popular brands including Merrell, Sperry, Saucony and Hush Puppies, serving outdoor, casual, workwear and athletic segments via e-commerce, retail stores and global wholesale networks.
EXEL vs WWW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $517.5M |
| Net Profit | $244.5M | $31.8M |
| Gross Margin | 95.6% | 47.3% |
| Operating Margin | 39.3% | 9.7% |
| Net Margin | 40.8% | 6.1% |
| Revenue YoY | 5.6% | 25.5% |
| Net Profit YoY | 74.8% | 162.8% |
| EPS (diluted) | $0.89 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | $517.5M | ||
| Q4 25 | $597.8M | — | ||
| Q3 25 | $568.3M | $470.3M | ||
| Q2 25 | $555.4M | $474.2M | ||
| Q1 25 | $566.8M | $412.3M | ||
| Q4 24 | — | $494.7M | ||
| Q3 24 | $539.5M | $440.2M | ||
| Q2 24 | $637.2M | $425.2M |
| Q1 26 | $244.5M | $31.8M | ||
| Q4 25 | $193.6M | — | ||
| Q3 25 | $184.8M | $25.1M | ||
| Q2 25 | $159.6M | $26.8M | ||
| Q1 25 | $139.9M | $12.1M | ||
| Q4 24 | — | $23.1M | ||
| Q3 24 | $118.0M | $23.2M | ||
| Q2 24 | $226.1M | $13.8M |
| Q1 26 | 95.6% | 47.3% | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | 47.5% | ||
| Q2 25 | 96.5% | 47.2% | ||
| Q1 25 | 96.5% | 47.2% | ||
| Q4 24 | — | 43.4% | ||
| Q3 24 | 96.8% | 45.1% | ||
| Q2 24 | 97.2% | 43.1% |
| Q1 26 | 39.3% | 9.7% | ||
| Q4 25 | 39.6% | — | ||
| Q3 25 | 37.6% | 8.4% | ||
| Q2 25 | 33.6% | 8.6% | ||
| Q1 25 | 28.8% | 4.8% | ||
| Q4 24 | — | 7.4% | ||
| Q3 24 | 25.2% | 7.9% | ||
| Q2 24 | 43.3% | 6.8% |
| Q1 26 | 40.8% | 6.1% | ||
| Q4 25 | 32.4% | — | ||
| Q3 25 | 32.5% | 5.3% | ||
| Q2 25 | 28.7% | 5.7% | ||
| Q1 25 | 24.7% | 2.9% | ||
| Q4 24 | — | 4.7% | ||
| Q3 24 | 21.9% | 5.3% | ||
| Q2 24 | 35.5% | 3.2% |
| Q1 26 | $0.89 | $0.37 | ||
| Q4 25 | $0.69 | — | ||
| Q3 25 | $0.65 | $0.30 | ||
| Q2 25 | $0.55 | $0.32 | ||
| Q1 25 | $0.47 | $0.15 | ||
| Q4 24 | — | $0.29 | ||
| Q3 24 | $0.40 | $0.28 | ||
| Q2 24 | $0.77 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | — |
| Total DebtLower is stronger | — | $621.7M |
| Stockholders' EquityBook value | $2.2B | $408.0M |
| Total Assets | $2.8B | $1.7B |
| Debt / EquityLower = less leverage | — | 1.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | — | ||
| Q3 25 | $791.1M | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.0B | — |
| Q1 26 | — | $621.7M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $676.4M | ||
| Q2 25 | — | $708.5M | ||
| Q1 25 | — | $710.8M | ||
| Q4 24 | — | $648.0M | ||
| Q3 24 | — | $702.8M | ||
| Q2 24 | — | $814.7M |
| Q1 26 | $2.2B | $408.0M | ||
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.0B | $376.7M | ||
| Q2 25 | $2.1B | $344.0M | ||
| Q1 25 | $2.2B | $310.6M | ||
| Q4 24 | — | $312.9M | ||
| Q3 24 | $2.3B | $295.2M | ||
| Q2 24 | $2.1B | $262.1M |
| Q1 26 | $2.8B | $1.7B | ||
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.7B | $1.7B | ||
| Q2 25 | $2.8B | $1.8B | ||
| Q1 25 | $2.9B | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $3.0B | $1.8B | ||
| Q2 24 | $2.8B | $1.8B |
| Q1 26 | — | 1.52× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | 2.06× | ||
| Q1 25 | — | 2.29× | ||
| Q4 24 | — | 2.07× | ||
| Q3 24 | — | 2.38× | ||
| Q2 24 | — | 3.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $146.2M |
| Free Cash FlowOCF − Capex | $332.4M | $145.6M |
| FCF MarginFCF / Revenue | 55.5% | 28.1% |
| Capex IntensityCapex / Revenue | 0.2% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.36× | 4.60× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $125.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | $146.2M | ||
| Q4 25 | $290.3M | — | ||
| Q3 25 | $49.0M | $33.0M | ||
| Q2 25 | $211.4M | $44.6M | ||
| Q1 25 | $240.3M | $-83.8M | ||
| Q4 24 | — | $82.4M | ||
| Q3 24 | $271.3M | $108.2M | ||
| Q2 24 | $119.5M | $26.7M |
| Q1 26 | $332.4M | $145.6M | ||
| Q4 25 | $288.8M | — | ||
| Q3 25 | $46.2M | $30.1M | ||
| Q2 25 | $208.5M | $41.2M | ||
| Q1 25 | $236.3M | $-91.4M | ||
| Q4 24 | — | $74.4M | ||
| Q3 24 | $263.1M | $104.1M | ||
| Q2 24 | $113.0M | $23.7M |
| Q1 26 | 55.5% | 28.1% | ||
| Q4 25 | 48.3% | — | ||
| Q3 25 | 8.1% | 6.4% | ||
| Q2 25 | 37.5% | 8.7% | ||
| Q1 25 | 41.7% | -22.2% | ||
| Q4 24 | — | 15.0% | ||
| Q3 24 | 48.8% | 23.6% | ||
| Q2 24 | 17.7% | 5.6% |
| Q1 26 | 0.2% | 0.1% | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.5% | 0.6% | ||
| Q2 25 | 0.5% | 0.7% | ||
| Q1 25 | 0.7% | 1.8% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | 1.5% | 0.9% | ||
| Q2 24 | 1.0% | 0.7% |
| Q1 26 | 1.36× | 4.60× | ||
| Q4 25 | 1.50× | — | ||
| Q3 25 | 0.27× | 1.31× | ||
| Q2 25 | 1.32× | 1.66× | ||
| Q1 25 | 1.72× | -6.93× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 2.30× | 4.66× | ||
| Q2 24 | 0.53× | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
WWW
| Sales Channel Through Intermediary | $230.2M | 44% |
| Sales Channel Directly To Consumer | $142.6M | 28% |
| Work Group | $134.0M | 26% |
| Other | $10.7M | 2% |
